



### Program

Tuesday, October 25

Nagano

#### Session 4: Novel Viral Platforms

Chairpersons: Kah-Whye Peng, Chae-Ok Yun

8:30-8:55

**INV12: Kah-Whye Peng**

*Mayo Clinic, USA*

Clinical activity with systemic Voyager-V1 VSV virotherapy in relapsed refractory malignancies

8:55-9:20

**INV13: Chae-Ok Yun**

*Hanyang University, GeneMedicine Co., Ltd., Seoul, Korea*

Nanomaterial-based delivery systems to overcome the limitations of oncolytic adenovirus

9:20-9:35

**INV14: Chieko Kai**

*Institute of Industrial Science, The University of Tokyo, Japan*

A recombinant measles virus, rMV-SLAMblind is a promising candidate for a novel oncolytic cancer therapy

9:35-9:50

**Oral 8: Taha Azad**

*Ottawa Hospital Research Institute, Ottawa, ON, Canada*

Conditionally replicating vaccinia virus platforms As alternatives to Modified Vaccinia Ankara for cancer immunotherapy

9:50-10:10

Coffee Break

Tuesday,  
October 25

**Tuesday, October 25**
**Nagano**
**Session 5: Clinical Trials**
**Chairpersons:** Evanthia Galanis, Kenzaburo Tani

10:10-10:35	<b>INV15: Evanthia Galanis</b> <i>Mayo Clinic, USA</i> Oncolytic Engineered Measles Virus strains for Glioma Immunovirotherapy
10:35-10:50	<b>INV16: Hiroshi Fukuhara</b> <i>Kyorin University, Japan</i> Phase 1 clinical trial of G47 $\Delta$ in patients with castration-resistant prostate cancer
10:50-11:05	<b>INV17: Toshihiko Okazaki</b> <i>Medical Center for Translational and Clinical Research, Dept. of Medical Innovation, Osaka University Hospital, Osaka, Japan</i> Establishing GMP compliant adenovirus serotype-35 manufacturing process development
11:05-11:20	<b>Oral 9: James Burke</b> <i>CG Oncology, USA</i> CG0070 for the treatment of non-muscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin (BCG)
11:20-11:35	<b>Oral 10: Frank Tufaro</b> <i>VCN Biosciences- Synthetic Biologics, Spain</i> VCN-01 changes tumor stroma when administered systemically in combination with Durvalumab (MEDI4736) in subjects with recurrent/ metastatic squamous cell carcinoma of the head and neck (R/ M HNSCC): Biological data of a Phase I Study
11:35-11:50	<b>Oral 11: Shruthi Naik</b> <i>Mayo Clinic Department of Molecular Medicine, USA</i> Intravesical oncolytic measles virus therapy for bladder cancer
11:50-12:05	<b>Oral 12: Siddhartha Yadav</b> <i>Department of Oncology, Mayo Clinic, Rochester, MN, USA</i> A first-in-human phase I clinical trial of intratumor administration of a measles virus derivative expressing the Helicobacter pylori neutrophil-activating protein in patients with metastatic breast cancer

**Tuesday,  
October 25**



### Program

Tuesday, October 25

Nagano

**Luncheon Seminar**

Chairperson: Norimitsu Kadowaki

12:15-13:15

**INV18: Masahiro Abe**

\*No on-demand

*Department of Hematology, Endocrinology and Metabolism, Tokushima University Graduate School, Tokushima, Japan*

Pathogenesis of bone destruction and tumor progression in multiple myeloma: the role of RANKL

Sponsored by Daiichi Sankyo Co., Ltd.

Tuesday, October 25

13:30-17:00

Excursion

Tuesday, October 25

**日本ウイルス療法学会発足記念講演**

**Inaugural Lecture for the establishment of the Japan Society of Oncolytic Virus Therapy**

Chairperson: Tomoki Todo

17:45-18:45

**Hiroyuki Mano**

*Director, Research Institute/Center for Cancer Genomics and Advanced Therapeutics, National Cancer Center*

がん研究が拓く未来の医療

Precision medicine driven by cancer research